• Home

  • Healthcare

  • Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac...
17

Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market

Embed Size (px)

Citation preview

Page 1: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 2: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 3: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 4: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 5: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 6: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 7: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 8: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 9: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 10: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 11: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 12: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 13: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 14: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 15: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 16: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 17: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market

Global Anticoagulants Market: Size, Trends & Forecasts ...daedal-research.com/uploads/images/full/3af6e... · The report entitled “ Global Anticoagulants Market: Size, Trends &

Global Anticoagulants Market: Size, Trends & Forecasts ...daedal-research.com/uploads/images/full/3af6e... · The report entitled “ Global Anticoagulants Market: Size, Trends &

Documents
URGENCES ET NOUVEAUX ANTICOAGULANTS ORAUX (NOACS) 05 14 Urgences... · 2013-08-22 · CHADS 2 2.1±1.1 VKA : 1.6% VKA : 3.1% IC bleed ↓ significantly (not RIV) but ↑ GI bleed

URGENCES ET NOUVEAUX ANTICOAGULANTS ORAUX (NOACS) 05 14 Urgences... · 2013-08-22 · CHADS 2 2.1±1.1 VKA : 1.6% VKA : 3.1% IC bleed ↓ significantly (not RIV) but ↑ GI bleed

Documents
AHS Powerpoint Template - KTPH - Practical... · 1 Practical Considerations on the Use of Novel Oral Anticoagulants (NOACs) in Stroke Patients with Non-valvular AF AHS-NNI Neuroscience

AHS Powerpoint Template - KTPH - Practical... · 1 Practical Considerations on the Use of Novel Oral Anticoagulants (NOACs) in Stroke Patients with Non-valvular AF AHS-NNI Neuroscience

Documents
313FM.5 DABIGATRAN, RIVAROXABAN, EDOXABAN AND APIXABAN … · anticoagulants (NOACs) are unlike warfarin as they are not vitamin K antagonists and do not require regular INR monitoring

313FM.5 DABIGATRAN, RIVAROXABAN, EDOXABAN AND APIXABAN … · anticoagulants (NOACs) are unlike warfarin as they are not vitamin K antagonists and do not require regular INR monitoring

Documents
Perioperative Management of Novel Oral Anticoagulants€¦ · Mekaj YH, et al. Therap & Clin Risk Management, 2015:11 967-977. NOACs vs Warfarin • Disadvantages: – Cost – Compliance

Perioperative Management of Novel Oral Anticoagulants€¦ · Mekaj YH, et al. Therap & Clin Risk Management, 2015:11 967-977. NOACs vs Warfarin • Disadvantages: – Cost – Compliance

Documents
NOACs in AF - Heart Group GP/NOACs i… · NOACS for AF True/False •All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF •NOACS are more effective than

NOACs in AF - Heart Group GP/NOACs i… · NOACS for AF True/False •All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF •NOACS are more effective than

Documents
Welcome to CDDW™ 2018! Dr. Roland Valori Making a Difference › images › cddw › cddw2018_finalprogram.pdf · NAFLD non-alcoholic fatty liver disease . NOACS new oral anticoagulants

Welcome to CDDW™ 2018! Dr. Roland Valori Making a Difference › images › cddw › cddw2018_finalprogram.pdf · NAFLD non-alcoholic fatty liver disease . NOACS new oral anticoagulants

Documents
Should noacs replace warfarin

Should noacs replace warfarin

Health & Medicine
Global Anticoagulants Market: Size, Trends & Forecasts (2016-2020) - New Report by Daedal Research

Global Anticoagulants Market: Size, Trends & Forecasts (2016-2020) - New Report by Daedal Research

Business
New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Educational

New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Educational

Documents
New Oral Anticoagulants - UCSF CME€¦ · New Oral Anticoagulants Management of the Hospitalized Patient San Francisco, CA 2014 Update in Nomenclature NOACs-new oral anticoagulants

New Oral Anticoagulants - UCSF CME€¦ · New Oral Anticoagulants Management of the Hospitalized Patient San Francisco, CA 2014 Update in Nomenclature NOACs-new oral anticoagulants

Documents
Use of Novel Anticoagulants (NOACs) in Stroke of New Oral Anticoagulants... · • Bleeding and its management • Follow-up . Vitamin K antagonists • Historically the standard

Use of Novel Anticoagulants (NOACs) in Stroke of New Oral Anticoagulants... · • Bleeding and its management • Follow-up . Vitamin K antagonists • Historically the standard

Documents
NONWARFARIN ORAL ANTICOAGULANTS (NOACS)4 NONWARFARIN ORAL ANTICOAGULANTS (NOACS): THE CLINICAL PHARMACIST’S PERSPECTIVE Atrial Fibrillation AF confers about a 5-fold increased risk

NONWARFARIN ORAL ANTICOAGULANTS (NOACS)4 NONWARFARIN ORAL ANTICOAGULANTS (NOACS): THE CLINICAL PHARMACIST’S PERSPECTIVE Atrial Fibrillation AF confers about a 5-fold increased risk

Documents
NOACS and bleeding

NOACS and bleeding

Health & Medicine
NOACs: Innovation in anticoagulation · 2016-09-20 · anticoagulation therapy are not receiving it, suggesting that there is substantial scope to improve the uptake of anticoagulants

NOACs: Innovation in anticoagulation · 2016-09-20 · anticoagulation therapy are not receiving it, suggesting that there is substantial scope to improve the uptake of anticoagulants

Documents
Case Studies for NOACs - JCR · Case Studies for NOACs Jong Sung Park, MD Dong-A University Hospital Joint meeting of Coronary Revascularization 2013 . Novel Oral Anticoagulants Used

Case Studies for NOACs - JCR · Case Studies for NOACs Jong Sung Park, MD Dong-A University Hospital Joint meeting of Coronary Revascularization 2013 . Novel Oral Anticoagulants Used

Documents
Role of novel oral anticoagulants in the management and ... · The novel oral anticoagulants (NOACs) have a fast onset of action and more predictable anticoagulation effect. Some

Role of novel oral anticoagulants in the management and ... · The novel oral anticoagulants (NOACs) have a fast onset of action and more predictable anticoagulation effect. Some

Documents
Dabigatran, rivaroxaban and apixaban, the new oral ... · PDF fileSecond Edition November 2013 Page 1 of 32 Dabigatran, rivaroxaban and apixaban, the new oral anticoagulants (NOACS),

Dabigatran, rivaroxaban and apixaban, the new oral ... · PDF fileSecond Edition November 2013 Page 1 of 32 Dabigatran, rivaroxaban and apixaban, the new oral anticoagulants (NOACS),

Documents
TSOACs, DOACs, and NOACs… OH MY! Drug Safety ......TSOACs, DOACs, and NOACs… OH MY! Drug Safety Considerations for Using Non -VKA Oral Anticoagulants Zachary R. Noel, PharmD, BCPS

TSOACs, DOACs, and NOACs… OH MY! Drug Safety ......TSOACs, DOACs, and NOACs… OH MY! Drug Safety Considerations for Using Non -VKA Oral Anticoagulants Zachary R. Noel, PharmD, BCPS

Documents
Antidote for NOACs

Antidote for NOACs

Health & Medicine
A Review of the Role of Non-Vitamin K Oral Anticoagulants ... · that evaluated these NOACs, patients received at least 5 days of parenteral anticoagulation with UFH or LMHW prior

A Review of the Role of Non-Vitamin K Oral Anticoagulants ... · that evaluated these NOACs, patients received at least 5 days of parenteral anticoagulation with UFH or LMHW prior

Documents
Global Anticoagulants Market (2019-2023 Edition)daedal-research.com/uploads/images/full/851dae14c8fe0ec9f2c2fa3… · Anticoagulants which are also known as blood thinners are drugs

Global Anticoagulants Market (2019-2023 Edition)daedal-research.com/uploads/images/full/851dae14c8fe0ec9f2c2fa3… · Anticoagulants which are also known as blood thinners are drugs

Documents
PCORI Funding Announcement: New Oral Anticoagulants …...PCORI Funding Announcement: New Oral Anticoagulants (NOACs) in the Extended Treatment of Venous Thromboembolic Disease . Published

PCORI Funding Announcement: New Oral Anticoagulants …...PCORI Funding Announcement: New Oral Anticoagulants (NOACs) in the Extended Treatment of Venous Thromboembolic Disease . Published

Documents
New Oral Anticoagulants (NOACs) - Tallahassee, FL/media/files/heart and vascular/heartsymposium...• Balance risks of bleeding vs risks of clotting – Patients at the highest risk

New Oral Anticoagulants (NOACs) - Tallahassee, FL/media/files/heart and vascular/heartsymposium...• Balance risks of bleeding vs risks of clotting – Patients at the highest risk

Documents
NOACs (new oral anticoagulants): are we ready for a wide use after stroke ? YES

NOACs (new oral anticoagulants): are we ready for a wide use after stroke ? YES

Documents
ISTH Guidance Statement on the Nomenclature for Oral ... · 25 anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 26 781-782). Thromb Haemost. 2014; 112:

ISTH Guidance Statement on the Nomenclature for Oral ... · 25 anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 26 781-782). Thromb Haemost. 2014; 112:

Documents
NOACs (new oral anticoagulants): are we ready for a wide use after stroke? YES George Ntaios University of Thessaly, Larissa, Greece 2013 Joint meeting

NOACs (new oral anticoagulants): are we ready for a wide use after stroke? YES George Ntaios University of Thessaly, Larissa, Greece 2013 Joint meeting

Documents
Novel Oral Anticoagulants (NOACs)cshp-ab.ca/_CMS/files/NOAC CSHP Sept 12 2015 Handout FINAL.pdf · Update on Oral Anticoagulants – ... Prosthesis is an artificial device used to

Novel Oral Anticoagulants (NOACs)cshp-ab.ca/_CMS/files/NOAC CSHP Sept 12 2015 Handout FINAL.pdf · Update on Oral Anticoagulants – ... Prosthesis is an artificial device used to

Documents
Non-Vitamin K Antagonist Oral Anticoagulants: New Choices ... · 32]. NOACs have fewer drug–drug and drug–food inter-actions than warfarin. Although rivaroxaban should be administered

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices ... · 32]. NOACs have fewer drug–drug and drug–food inter-actions than warfarin. Although rivaroxaban should be administered

Documents
Deciphering the Maze of Evidence from Landmark Trials Evaluating Non-Monitored, Oral Anticoagulants (NOACs) for SPAF New Paradigms in the Science and Medicine

Deciphering the Maze of Evidence from Landmark Trials Evaluating Non-Monitored, Oral Anticoagulants (NOACs) for SPAF New Paradigms in the Science and Medicine

Documents